FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

3 Observations from Lupin Pithampur Inspection

FDA releases the form FDA-483 with three observations from its inspection at the Lupin drug manufacturing facility in Pithampur, Madhya Pradesh, India...

latest-news-card-1
Human Drugs

Orphan Status for Minovia Myelodysplastic Drug

Minovia Therapeutics wins an FDA orphan drug designation for its lead investigational therapy, MNV-201, for myelodysplastic syndrome.

latest-news-card-1
Human Drugs

FDA Accepts Chiesis Triple Combination Asthma Inhaler

FDA accepts for review a Chiesi NDA for a single-inhaler triple therapy designed for the maintenance treatment of asthma in adults.

latest-news-card-1
Human Drugs

Former Deputy Commissioner Bumpus Joins Charles River

Charles River Laboratories names former FDA principal deputy commissioner Namandj N. Bumpus as chair a new global scientific advisory board to guide t...

latest-news-card-1
Medical Devices

FDA Warns on RF Microneedling Devices

FDA warns of serious complications associated with certain uses of radiofrequency microneedling devices, commonly used in aesthetic skin treatments.

Human Drugs

Trial Success for Lilly Oral GLP-1

Lilly says its investigational oral GLP-1 drug demonstrated good glycemic control in two Phase 3 trials.

Medical Devices

FDA Clears Roche Alzheimers Test

FDA clears Roches Elecsys pTau 181 blood-based biomarker test for an initial Alzheimers disease assessment.

latest-news-card-1
Human Drugs

6 Observations in Hetero Labs 483

FDA releases the 12-page form FDA-483 with six observations from an inspection at Indias Hetero Labs Unit 9 API manufacturing facility.

latest-news-card-1
Human Drugs

Akamis Bio Gets Fast Track for Rectal Cancer Drug

FDA grants Akamis Bio a fast-track designation to NG-350A for treating mismatch repair-proficient locally advanced rectal cancer.

latest-news-card-1
Human Drugs

Pluses, Minuses to FDA Oncology Trial Guidance

Oncologist John Burke analyzes the positive and potentially negative impacts of FDAs new guidance on overall survival as an endpoint in oncology trial...